Your browser doesn't support javascript.
loading
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.
Holkova, Beata; Zingone, Adriana; Kmieciak, Maciej; Bose, Prithviraj; Badros, Ashraf Z; Voorhees, Peter M; Baz, Rachid; Korde, Neha; Lin, Hui-Yi; Chen, Jin-Qiu; Herrmann, Michelle; Xi, Liqiang; Raffeld, Mark; Zhao, Xiuhua; Wan, Wen; Tombes, Mary Beth; Shrader, Ellen; Weir-Wiggins, Caryn; Sankala, Heidi; Hogan, Kevin T; Doyle, Austin; Annunziata, Christina M; Wellons, Martha; Roberts, John D; Sullivan, Daniel; Landgren, Ola; Grant, Steven.
Afiliación
  • Holkova B; Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia. Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia. beata.holkova@vcuhealth.org stgrant@vcu.edu.
  • Zingone A; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Kmieciak M; Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia.
  • Bose P; Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia. Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia.
  • Badros AZ; Department of Medicine, Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland.
  • Voorhees PM; Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
  • Baz R; Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center, Tampa, Florida.
  • Korde N; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Lin HY; Department of Biostatistics and Biomedical Informatics, H. Lee Moffitt Cancer Center, Tampa, Florida.
  • Chen JQ; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Herrmann M; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Xi L; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Raffeld M; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Zhao X; Department of Biostatistics and Biomedical Informatics, H. Lee Moffitt Cancer Center, Tampa, Florida.
  • Wan W; Department of Biostatistics, Virginia Commonwealth University, Richmond, Virginia.
  • Tombes MB; Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia.
  • Shrader E; Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia.
  • Weir-Wiggins C; Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia.
  • Sankala H; Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia.
  • Hogan KT; Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia.
  • Doyle A; Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Annunziata CM; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Wellons M; Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia.
  • Roberts JD; Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia. Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia.
  • Sullivan D; Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center, Tampa, Florida.
  • Landgren O; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Grant S; Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia. Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia. Department of Microbiology and Immunology, Virginia Commonwealth University, Richmond, Virginia. Department of Biochemistry and Molecular
Clin Cancer Res ; 22(5): 1067-75, 2016 Mar 01.
Article en En | MEDLINE | ID: mdl-26446942
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 3_ND Problema de salud: 3_diarrhea Asunto principal: Bencimidazoles / Mieloma Múltiple / Recurrencia Local de Neoplasia Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 3_ND Problema de salud: 3_diarrhea Asunto principal: Bencimidazoles / Mieloma Múltiple / Recurrencia Local de Neoplasia Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article